173 related articles for article (PubMed ID: 26934318)
21. A phase II study of preoperative chemoradiation with tegafur-uracil plus leucovorin for locally advanced rectal cancer with pharmacogenetic analysis.
Kim SY; Baek JY; Oh JH; Park SC; Sohn DK; Kim MJ; Chang HJ; Kong SY; Kim DY
Radiat Oncol; 2017 Mar; 12(1):62. PubMed ID: 28347333
[TBL] [Abstract][Full Text] [Related]
22. Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response.
Balboa E; Duran G; Lamas MJ; Gomez-Caamaño A; Celeiro-Muñoz C; Lopez R; Carracedo A; Barros F
Pharmacogenomics; 2010 Jun; 11(6):747-61. PubMed ID: 20504250
[TBL] [Abstract][Full Text] [Related]
23. Does residual microscopic disease after chemoradiotherapy for locally advanced rectal cancer translate into a good clinical outcome?
Geva R; Davidovics H; Soyfer S; Pelles-Avraham S; Klausner JM; Inbar M; Tulchinsky H
Colorectal Dis; 2017 Mar; 19(3):237-242. PubMed ID: 27474791
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-21 predicts response to preoperative chemoradiotherapy in locally advanced rectal cancer.
Caramés C; Cristóbal I; Moreno V; del Puerto L; Moreno I; Rodriguez M; Marín JP; Correa AV; Hernández R; Zenzola V; Hernández T; León A; Martín JI; Sánchez-Fayos P; García-Olmo D; Rojo F; Goel A; Fernandez-Aceñero MJ; García-Foncillas J
Int J Colorectal Dis; 2015 Jul; 30(7):899-906. PubMed ID: 25953218
[TBL] [Abstract][Full Text] [Related]
25. Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT.
Shanmugan S; Arrangoiz R; Nitzkorski JR; Yu JQ; Li T; Cooper H; Konski A; Farma JM; Sigurdson ER
Ann Surg Oncol; 2012 Jul; 19(7):2178-85. PubMed ID: 22395978
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of clinical and pathological stages on locally advanced rectal carcinoma after neoadjuvant chemoradiotherapy.
Wen B; Zhang L; Wang C; Huang R; Peng H; Zhang T; Dong J; Xiao W; Zeng Z; Liu M; Gao Y
Radiat Oncol; 2015 Jun; 10():124. PubMed ID: 26040453
[TBL] [Abstract][Full Text] [Related]
27. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
Bertolini F; Bengala C; Losi L; Pagano M; Iachetta F; Dealis C; Jovic G; Depenni R; Zironi S; Falchi AM; Luppi G; Conte PF
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1455-61. PubMed ID: 17445998
[TBL] [Abstract][Full Text] [Related]
28. SMAD3 Host and Tumor Profiling to Identify Locally Advanced Rectal Cancer Patients at High Risk of Poor Response to Neoadjuvant Chemoradiotherapy.
De Mattia E; Canzonieri V; Polesel J; Mezzalira S; Dalle Fratte C; Dreussi E; Roncato R; Bignucolo A; Innocente R; Belluco C; Pucciarelli S; De Paoli A; Palazzari E; Toffoli G; Cecchin E
Front Pharmacol; 2021; 12():778781. PubMed ID: 35002714
[TBL] [Abstract][Full Text] [Related]
29. miR-194 as predictive biomarker of responsiveness to neoadjuvant chemoradiotherapy in patients with locally advanced rectal adenocarcinoma.
D'Angelo E; Zanon C; Sensi F; Digito M; Rugge M; Fassan M; Scarpa M; Pucciarelli S; Nitti D; Agostini M
J Clin Pathol; 2018 Apr; 71(4):344-350. PubMed ID: 28870889
[TBL] [Abstract][Full Text] [Related]
30. Disease Control, Survival, and Toxicity Outcome After Intensified Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Single-Institution Experience.
De Felice F; Musio D; Magnante AL; Bulzonetti N; Benevento I; Caiazzo R; Tombolini V
Clin Colorectal Cancer; 2016 Jun; 15(2):e17-22. PubMed ID: 26952656
[TBL] [Abstract][Full Text] [Related]
31. The role of epithelial mesenchymal transition and resistance to neoadjuvant therapy in locally advanced rectal cancer.
Bhangu A; Wood G; Brown G; Darzi A; Tekkis P; Goldin R
Colorectal Dis; 2014 Apr; 16(4):O133-43. PubMed ID: 24617665
[TBL] [Abstract][Full Text] [Related]
32. The role of tissue diagnosis prior to neoadjuvant chemoradiotherapy for locally advanced rectal cancer.
Daniel ES; Gibbs P; Guerrieri M; Faragher I
Colorectal Dis; 2014 Oct; 16(10):783-7. PubMed ID: 24786681
[TBL] [Abstract][Full Text] [Related]
33. [Research progress on pathologic complete response after neoadjuvant chemoradiotherapy for locally advanced rectal cancer].
Peng HH; You KY; Gao YH; Wen BX
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Jun; 16(6):592-6. PubMed ID: 23801217
[TBL] [Abstract][Full Text] [Related]
34. Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: Results of the BRANCH trial.
Avallone A; Pecori B; Bianco F; Aloj L; Tatangelo F; Romano C; Granata V; Marone P; Leone A; Botti G; Petrillo A; Caracò C; Iaffaioli VR; Muto P; Romano G; Comella P; Budillon A; Delrio P
Oncotarget; 2015 Oct; 6(30):30394-407. PubMed ID: 26320185
[TBL] [Abstract][Full Text] [Related]
35. Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemoradiation.
Lin CY; Tian YF; Wu LC; Chen LT; Lin LC; Hsing CH; Lee SW; Sheu MJ; Lee HH; Wang YH; Shiue YL; Wu WR; Huang HY; Hsu HP; Li CF; Chen SH
J Clin Pathol; 2012 Aug; 65(8):687-92. PubMed ID: 22569540
[TBL] [Abstract][Full Text] [Related]
36. The prognostic value of lymph node metastases and tumour regression grade in rectal cancer patients treated with long-course preoperative chemoradiotherapy.
Lindebjerg J; Spindler KL; Ploen J; Jakobsen A
Colorectal Dis; 2009 Mar; 11(3):264-9. PubMed ID: 18573119
[TBL] [Abstract][Full Text] [Related]
37. [Evaluation of preoperative radiotherapy or chemoradiotherapy in sphincter preservation for locally advanced middle-low rectal cancer].
Cao WG; Zhao R; Xi WQ; Ma T; Li H; Xu HP; Che JF; Jin YN
Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):225-7. PubMed ID: 17649643
[TBL] [Abstract][Full Text] [Related]
38. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
39. Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes.
Páez D; Salazar J; Paré L; Pertriz L; Targarona E; del Rio E; Barnadas A; Marcuello E; Baiget M
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1319-27. PubMed ID: 21570215
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients.
Lopes-Ramos CM; Habr-Gama A; Quevedo Bde S; Felício NM; Bettoni F; Koyama FC; Asprino PF; Galante PA; Gama-Rodrigues J; Camargo AA; Perez RO; Parmigiani RB
BMC Med Genomics; 2014 Dec; 7():68. PubMed ID: 25496125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
